Educational information only. Not medical advice.
Compare compounds, understand the differences, and explore the original studies behind them.
Research reviewed October 15, 2026. Start with the overview, then explore the evidence and sources.
Stages summarize the study designs available for the identified material in this selection. Human stages require studies in which people received that material; measuring the body’s own peptide or testing a different analogue does not qualify. Controlled studies can measure hormone responses or other biological changes, as well as clinical outcomes. A higher stage can include unsuccessful trials; the adjacent summary explains the findings and limitations.
Multiple reports from one trial count as one study for this classification. The selected-report totals below describe library coverage. Outcome-specific certainty would require a separate assessment of study limitations, consistency, applicability, precision and publication bias.
Retatrutide, also called LY3437943, is a single engineered peptide that activates three hormone receptors.
Tirzepatide is a modified, 39-amino-acid peptide based on GIP, a hormone released in response to nutrients.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. Defined subgroups of an obesity trial also examine knee-osteoarthritis pain and obstructive sleep apnea, measuring complications beyond weight change alone.
FDA-approved tirzepatide formulations cover type 2 diabetes from age ten, long-term weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro also covers cardiovascular risk reduction in adults with type 2 diabetes at high risk.
The categories describe the most advanced study designs selected for this library. Each summary explains what was measured and what remains uncertain.
Multiple controlled human studies
Separate phase 2 and phase 3 controlled trials reported substantial weight loss, with and without diabetes, and lower average blood glucose in diabetes trials. Obesity-complication findings come from defined subgroups. Trial duration, background medicines and analyses that handle treatment stopping differently matter when comparing the reported percentages.
Multiple controlled human studies
Large, separate controlled trials found weight loss, fewer sleep-breathing interruptions and fewer worsening-heart-failure events in their defined populations. SURPASS-CVOT found tirzepatide was not unacceptably worse than dulaglutide for cardiovascular events, meeting its noninferiority requirement. Its favorable numerical event difference did not establish superiority. Heart-failure mortality findings were also imprecise.
GIP means glucose-dependent insulinotropic polypeptide; GLP-1 means glucagon-like peptide 1. These hormone receptors help regulate metabolism. Receptor targets describe pharmacology; a clinical advantage needs a direct outcome comparison.
Retatrutide is one molecule activating GIP, GLP-1 and glucagon receptors. Its published 2026 phase 3 obesity trial measured weight and defined complication subgroups; the receptor combination alone does not establish superiority to tirzepatide.
Tirzepatide activates GIP and GLP-1 receptors. The current Zepbound label describes appetite and food-intake effects and product-specific clinical uses; it does not establish how it compares with retatrutide.
These are separate placebo-controlled trials without diabetes, with 80 weeks of retatrutide follow-up and 72 weeks for tirzepatide. Both program designs included diet/activity support. The reported principal analyses estimate outcomes while accounting for events such as stopping assigned treatment.
TRIUMPH-1 randomized 2,339 adults. Mean weight fell 17.6%, 23.7% and 25.0% across assigned retatrutide groups, versus 3.9% with placebo at 80 weeks. The two higher groups’ differences from placebo were 19.8 and 21.0 percentage points (P<0.001 for both), using the treatment-regimen analysis.
SURMOUNT-1 randomized 2,539 adults. At 72 weeks, mean weight fell 15.0%, 19.5% and 20.9% across assigned tirzepatide groups, versus 3.1% with placebo. The highest group’s mean reduction had a 95% CI of 19.9–21.8%; the treatment-regimen analysis included treatment discontinuation.
The official TRIUMPH-5 listing describes the planned direct comparison and an 800-person enrollment goal, with dates through December 2026. No comparative outcome was present in the accessed listing on October 15.
Its larger numerical average in TRIUMPH-1 does not estimate a direct advantage over tirzepatide. The trial used placebo and 80 weeks of follow-up; TRIUMPH-5 is the relevant direct comparison still awaiting an outcome report in the accessed official sources.
SURMOUNT-1 used placebo and 72 weeks of follow-up. Comparing its 20.9% average with a different retatrutide trial cannot establish that tirzepatide is inferior. The direct TRIUMPH-5 result was unavailable in the accessed official listing.
The estimates describe drug removal from blood in different studies and populations. A half-life is not a comparative clinical outcome.
The early 12-week phase 1b study in type 2 diabetes estimated a half-life of approximately six days after injections under the skin. It did not compare long-term weight loss with tirzepatide.
The Zepbound label reports approximately five to six days in people with overweight or obesity, including those with sleep apnea. This similar elimination timescale cannot establish equivalent or superior weight reduction.
Safety percentages below come from distinct populations and trials. They need their own denominators and do not supply a direct risk comparison.
In TRIUMPH-2’s highest group, type 2 diabetes participants had diarrhea in 34% versus 13% with placebo and nausea in 28% versus 8%. Low blood pressure and altered skin sensations were also more frequent. These results do not estimate safety relative to tirzepatide.
SURMOUNT-1 reported mostly mild-to-moderate digestive events. Across the active groups, 4.3–7.1% of participants stopped treatment because of adverse events, compared with 2.6% given placebo. The approved label also warns about severe digestive reactions, pancreatitis, gallbladder disease and kidney injury from dehydration. No cited direct trial establishes lower risk than retatrutide.
Gastrointestinal events recur across the retatrutide trials. In the phase 2 obesity study, heart-rate increases peaked at 24 weeks and subsequently declined. TRIUMPH-2 also found more low blood pressure (hypotension) and dysesthesia, an altered or unpleasant skin sensation, with retatrutide. Dysesthesia occurred in 4%–7% of active-group participants versus 1% with placebo. Permanent discontinuation because of adverse events or death occurred in 12% and 8% of the two higher-assignment groups, compared with 4% in the lowest group and 5% with placebo. Investigators considered the reported deaths unrelated to the intervention. These observations make tolerability and treatment continuation integral to interpretation of the weight results. Jastreboff et al. (2023), Bellido et al. (2026).
Nausea, diarrhea, vomiting, constipation and abdominal discomfort are common. Important risks include severe gastrointestinal symptoms, dehydration-associated kidney injury, gallbladder disease, pancreatitis, serious allergy, and low blood glucose when combined with insulin or a medicine that stimulates insulin release. The Zepbound label includes the risk of stomach contents entering the lungs around anesthesia and an August 2026 warning about damage to the retina addressing temporary worsening with rapid glucose improvement. The current label does not recommend use in severe gastroparesis, in which the stomach empties very slowly.
These are selected reports; several reports can come from one trial or cohort. Counts describe this library’s coverage.
No sections match this focus. Choose All sections to read the full comparison.
Read how the compounds differ, what direct studies found, and which questions remain open.
BPC-157 has been studied in several animal injury models and a few small human reports. Research on the defined acetylated TB-500 fragment is largely analytical or laboratory work. A small 2026 rat study tested BPC-157 alongside a TB-500-labeled preparation, but the paper did not fully identify that preparation or establish a clear difference between the two compounds.
CJC-1295 with DAC was designed to bind albumin and prolong growth-hormone signaling, and early studies measured its persistence and hormone effects in healthy volunteers. Modified GRF(1–29) shares the modified GHRH core but lacks that extension; most selected reports concern chemical identification, leaving much less human pharmacology to compare.
Direct trials found greater average weight and blood-glucose reductions with tirzepatide at the formulations tested. Receptor biology, available products, approved uses, cardiovascular outcomes and tolerability add context when comparing the two medicines.
Liraglutide and semaglutide activate the same GLP-1 receptor. Direct trials found larger average weight and blood-glucose reductions with semaglutide under the protocols tested. The comparison explains those trials, formulation differences, tolerability and separate cardiovascular evidence.
ACHIEVE-3 directly compared oral orforglipron capsules with oral semaglutide tablets in adults with type 2 diabetes taking metformin. Orforglipron lowered average blood glucose more. More participants reported stomach or intestinal adverse events or stopped treatment because of adverse events, and the average pulse increase was larger with orforglipron. The results concern the trial formulations and strengths; weight-management products need separate context.
Dihexa is a defined synthetic peptidomimetic with rodent research and important publication warnings. Cerebrolysin is a porcine-brain-derived mixture with randomized human trials, including favorable rehabilitation findings and unsuccessful acute-stroke comparisons. There is no direct trial establishing which is more effective or safer, and neither a shared brain-research theme nor separate study results makes the preparations interchangeable.
Semax is a seven-amino-acid peptide with small human neurological and brain-imaging reports. Dihexa is an angiotensin-IV-derived peptidomimetic with rodent research, a formal concern on its early pharmacology report and a retracted mechanism paper. Their separate studies do not establish which improves human memory more, and neither record provides a dependable human half-life comparison.
Epitalon studies focus on telomere maintenance, while FOXO4-DRI studies test removal of senescent cells. Separate mouse results, failed cartilage improvement and a pulmonary-vessel harm signal do not establish which would improve human aging. Neither has a validated human blood half-life in the sources reviewed here.
FOXO4-DRI experiments test senescent-cell clearance; MOTS-c experiments examine metabolic adaptation and physical capacity. Separate mouse results and human endogenous-MOTS-c measurements do not establish a clinical aging or fitness ranking. A pulmonary-vessel harm signal for FOXO4-DRI and major native-MOTS-c safety gaps remain consequential.
Retatrutide activates GIP, GLP-1 and glucagon receptors; semaglutide activates GLP-1 receptors. Separate placebo-controlled obesity trials found substantial weight loss with each, but their percentages cannot establish which works better in a shared population. Semaglutide has approved products and cardiovascular-outcome evidence. Retatrutide remains investigational, with a direct semaglutide diabetes comparison registered but no result report located for this review.
Three direct trials have preliminary sponsor results. REDEFINE 4 in obesity failed to establish CagriSema noninferiority to tirzepatide for weight loss. In type 2 diabetes, higher-dose REIMAGINE 4 met weight noninferiority but failed the glucose criterion; lower-dose REIMAGINE 5 reported greater weight loss with CagriSema and met glucose noninferiority. Exact doses, populations and analysis assumptions determine what each result means.
GHK-Cu combines a three-amino-acid peptide with copper; BPC-157 is a separate fifteen-amino-acid peptide. GHK-Cu has been tested in specific topical skin and wound products, with mixed human results. BPC-157 has repair-related cell and animal findings and small human reports. No direct GHK-Cu–BPC-157 trial was identified, so these sources cannot establish which improves skin or injury recovery more.
Analytical studies identify TB-500 as the acetylated seven-amino-acid thymosin β4 fragment Ac-LKKTETQ. GHK-Cu is a copper-bound tripeptide studied in specific skin and wound preparations. TB-500 fragment findings involve analytical and cell studies; GHK-Cu has mixed human topical findings. Full-length thymosin β4 trials and ambiguously named products cannot establish a fragment-versus-GHK-Cu clinical ranking.
Semax and Selank are different seven-residue peptides with a shared Pro-Gly-Pro ending. Their patient studies addressed different conditions: stroke-related deficits for Semax and anxiety-related symptoms for Selank. A small study included both compounds and placebo in healthy participants, but measured brain-scan connectivity rather than clinical benefit. These sources cannot rank them as treatments for anxiety, cognition or stroke.
Oxytocin is an endogenous hormone with established obstetric uses; its sexual-function studies used particular nasal or vaginal preparations in distinct populations. Bremelanotide, also called PT-141, is a melanocortin-receptor agonist approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Separate trials cannot establish which is a better treatment for a shared patient group.
GHRP-6 and GHRP-2 are different six-residue peptides that stimulate growth hormone through the ghrelin-receptor system. Controlled GHRP-2 meal studies found greater food intake, while GHRP-6 has direct human peptide measurements and detailed endocrine experiments. These sources do not establish which produces more muscle, better recovery or a stronger appetite effect in a direct comparison.
Ipamorelin stimulates the ghrelin receptor; tesamorelin stimulates the growth hormone-releasing factor receptor. Ipamorelin’s bowel-surgery trial observed earlier meal tolerance but did not establish a benefit over placebo. Tesamorelin reduced visceral abdominal fat in adults with HIV lipodystrophy and has an approved product for that setting. Their trials do not establish relative muscle growth, recovery or general weight-loss effects.
BPC-157 and KPV have both been investigated in intestinal injury models, but they are different peptides with different experimental explanations. BPC-157, called BPC-15 in the rat report, reduced chemical colon injury when injected into the abdomen before the injury; KPV studies connected cellular peptide transport with reduced inflammation in mouse colitis. Neither literature establishes which is more effective or safer for human inflammatory bowel disease.
BPC-157 and LL-37 have been studied in wound-related research, but their results come from different settings. BPC-157 accelerated closure of chemical burns in rats. LL-37 has randomized topical ulcer trials in people: an early study found faster wound shrinkage, while the larger trial did not establish better complete closure overall. These sources do not compare the peptides directly or support a general healing ranking.
MOTS-c is a mitochondrial-encoded peptide studied in cells, mouse interventions and human measurements of the body’s own peptide. SS-31 is a development name for elamipretide, which acts at mitochondrial membranes and has controlled patient trials. Its large mitochondrial-myopathy trial did not establish better walking or fatigue, while its defined product has accelerated approval for muscle strength in Barth syndrome. These findings cannot rank the compounds for general energy, exercise or aging.
AOD9604 is a modified growth-hormone fragment whose oral obesity program failed to establish useful weight loss. Semaglutide activates the GLP-1 receptor and produced substantially greater weight reduction than placebo in STEP 1. No direct randomized comparison establishes their relative effect or safety; the informative contrast is between their different controlled human results.
Retatrutide activates GIP, GLP-1 and glucagon receptors; tirzepatide activates GIP and GLP-1 receptors. Both have substantial placebo-controlled weight-loss results, but the trials differ in duration, population and analysis. Retatrutide remains investigational in October 2026, and the registered direct TRIUMPH-5 comparison has no outcome result in the accessed official listing.
Retatrutide is one peptide activating GIP, GLP-1 and glucagon receptors. CagriSema combines the amylin analogue cagrilintide with semaglutide, a GLP-1 receptor agonist. Both have substantial placebo-controlled human weight-loss findings, including separate trials with type 2 diabetes, but no direct randomized comparison in the selected sources establishes which is more effective or safer. Both remain investigational as of October 2026.
CJC-1295 with a drug affinity complex (DAC) binds albumin, a blood protein, and stimulates the receptor for growth hormone-releasing hormone (GHRH). Small healthy-adult studies found prolonged growth hormone (GH) and insulin-like growth factor 1 (IGF-1) increases with this form. Ipamorelin acts through the ghrelin-receptor system; a human infusion study measured a shorter peptide half-life, and its bowel-surgery trial left clinical benefit uncertain. No cited trial establishes which improves muscle growth, recovery or longevity.
Hexarelin and ipamorelin stimulate growth hormone through the ghrelin-receptor system, but their research differs. Small human hexarelin experiments measured brief cardiac changes and a smaller growth hormone (GH) response during repeated exposure. Ipamorelin has animal selectivity data, a human infusion study and a postoperative trial with uncertain clinical benefit. These findings do not establish which provides better muscle growth or long-term safety.
Ipamorelin acts through the ghrelin-receptor system. Sermorelin is the amidated fragment containing the first twenty-nine residues of growth hormone-releasing hormone (GHRH) and stimulates its receptor. Ipamorelin’s postoperative trial left meal-tolerance benefit uncertain. Historical sermorelin research measured growth in children deficient in growth hormone (GH) and body composition in a small HIV study. Neither literature establishes superior healthy-adult muscle growth, recovery or anti-aging effects.
AOD-9604 is a modified fragment of growth hormone investigated for metabolic effects; its major oral obesity study did not establish greater weight loss than placebo. Tesamorelin stimulates growth hormone release and reduced fat around abdominal organs in adults with HIV and lipodystrophy. Its approved use concerns that specific fat distribution, with little overall weight change. The two compounds have not been compared directly in the selected trials.
Ipamorelin and GHRP-2 stimulate the ghrelin-receptor system. Their research differs: ipamorelin’s often-cited selectivity result comes from animals, and its human bowel-surgery trial left clinical benefit uncertain. GHRP-2 increased how much people ate in small controlled meal experiments. These findings do not establish a ranking for muscle growth, injury recovery or long-term safety.
Sermorelin is the amidated first twenty-nine residues of growth hormone-releasing hormone. Its studies include growth in children with diagnosed growth hormone deficiency. CJC-1295 with a drug affinity complex (DAC) is a modified albumin-binding analogue whose healthy-adult trials measured prolonged hormone increases. Their different molecular forms, populations and outcomes do not establish which improves adult strength, recovery or aging.
BPC-157 and ipamorelin intersect with growth-hormone biology at different points. BPC-157 increased growth-hormone receptors in rat tendon cells; ipamorelin stimulated growth-hormone release in human exposure research. BPC-157 also improved rat tendon-repair measurements, while ipamorelin’s postoperative meal-tolerance trial left benefit uncertain. These studies do not establish which improves human injury recovery or whether combining them helps.
GHK-Cu is a copper-bound tripeptide studied in connective-tissue biology and specific topical skin and ulcer preparations. Epithalon, also called Epitalon, is AEDG, a four-residue peptide studied in telomere maintenance and aging-related models. GHK-Cu’s human skin results vary by preparation and setting; Epitalon’s telomere findings do not establish human rejuvenation. No direct trial identified here ranks their effects on skin aging or longevity.
Epithalon, also called Epitalon, is the four-residue peptide AEDG studied in telomere and circadian biology. Thymosin alpha-1 is a separate N-acetylated 28-residue peptide with immune-cell experiments and controlled clinical trials. Its larger corrected sepsis trial did not establish a mortality reduction. Epitalon’s cellular and limited human-biomarker findings do not supply a human longevity benefit, and the two compounds have no direct clinical comparison in the sources reviewed here.
Bremelanotide and Melanotan II are related cyclic melanocortin peptides with different clinical evidence. The approved bremelanotide acetate injection improved desire and related distress in selected premenopausal women, while small Melanotan II studies measured pigmentation and acute erections in men. No selected head-to-head trial establishes a better or safer treatment.
Semax and bremelanotide are both short synthetic peptides related to hormone biology, but their studies ask different questions. Semax reports concern brain signaling and neurological illness; bremelanotide trials concern desire and related distress in premenopausal women with hypoactive sexual desire disorder, meaning persistent low desire that causes distress. No selected trial compares them for memory, stroke recovery or sexual symptoms.
Thymosin alpha-1 and LL-37 both participate in immune biology, but the selected clinical studies test different interventions. Thymosin alpha-1 was injected as an adjunct to sepsis care; synthetic LL-37 was applied to chronic leg ulcers. Larger trials did not establish the hoped-for overall mortality or ulcer-closure benefits, while earlier favorable findings and biological activity remain important to understand.